ScientificScholar®
Knowledge is power
Publisher of Scientific Journals

https://mentalhealthbulletin.org/

Academic Bulletin of Mental Health




*Review Article*

# The Impact of Chemotherapy on Cognitive Function: A Comprehensive Review of Cancer-related Cognitive Impairment and Treatment Options

Kuleshwar Sahu[1], M.Pharm, Sophiya Tiwari[1], B.Pharm

[1]Department of Pharmacology, School of Pharmacy, Chouksey Engineering College Bilaspur, Chhattisgarh, India

***Corresponding author:**
Mr. Kuleshwar Sahu,
Department of Pharmacology,
School of Pharmacy, Chouksey
Engineering College, Bilaspur,
Chhattisgarh, India.

sahukuleshwar2258@gmail.com

Received: 09 January 2025
Accepted: 04 February 2025
Published: 22 May 2025

**DOI** 10.25259/ABMH_1_2025

**Quick Response Code:**

## ABSTRACT

Cancer-related cognitive impairment (CRCI), commonly known as "chemo brain," is a significant neurocognitive complication associated with cancer treatments, particularly chemotherapy. Affecting 17% to 75% of cancer survivors, CRCI manifests as deficits in memory, learning, and processing speed, primarily due to neuroinflammation, oxidative stress, mitochondrial dysfunction, and hippocampal impairment. The diagnosis of CRCI is based on self-reported symptoms, neuropsychological evaluations, and advanced neuroimaging methods like functional magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. However, the lack of established biomarkers remains a challenge, hindering early detection and the development of personalized treatment approaches. Current management strategies focus on cognitive rehabilitation, pharmacological agents, and lifestyle interventions, including physical exercise and mindfulness-based therapies. Additionally, neuroprotective strategies, such as anti-inflammatory and antioxidant therapies, are emerging as potential treatment options. Case studies highlight the variability in CRCI severity and recovery, emphasizing the need for personalized interventions and baseline cognitive assessments to track post-treatment changes. The overlap of CRCI symptoms with conditions such as depression and anxiety further complicates its diagnosis and management. Addressing CRCI requires a multidisciplinary approach integrating cognitive, pharmacological, and behavioral therapies. Future research should prioritize refining diagnostic methods, exploring novel therapeutic strategies, and developing targeted interventions to improve cognitive health and overall quality of life in cancer survivors.

**Keywords:** Biomarkers, Cancer-related cognitive impairment, Chemotherapy, Neuroimaging, Neuroinflammation

## INTRODUCTION

Cancer-related cognitive Impairment (CRCI), also known as "chemo brain," is a neurocognitive complication commonly associated with cancer treatments, particularly chemotherapy, and has drawn significant attention in both clinical and research settings due to its profound impact on the quality of life (QoL) of survivors. First identified in the mid-20th century, CRCI manifests through a range of symptoms, including memory lapses, reduced executive functioning, concentration difficulties, attention deficits, and slower cognitive processing speeds, persisting for months or years after treatment.[1] Epidemiological data suggest that CRCI affects an estimated 17% to 75% of cancer survivors worldwide, with the increasing global prevalence of cancer further emphasizing the importance of this condition. In India, the National Cancer Registry Program reported rising cancer rates, with 94.1 cases per 100,000 males and 103.6 cases per 100,000 females in 2020, indicating an increasing burden of cancer and its associated complications, such as CRCI.[2] The pathogenesis of CRCI is still incompletely understood but is believed to be multifactorial. It involves mechanisms such as neuroinflammation triggered by chemotherapy

agents, oxidative stress, mitochondrial dysfunction, disruption of the blood-brain barrier, and interference with hippocampal neurogenesis. Genetic factors, including polymorphisms in the *APOE* gene, as well as modifiable risk factors like age, psychological distress, and comorbid conditions such as anemia and metabolic syndromes, further complicate the etiology of this condition.[3] The diagnosis of CRCI relies heavily on subjective self-reports from patients, structured neuropsychological assessments, and advanced neuroimaging techniques, such as functional MRI and positron emission tomography, which can detect alterations in brain connectivity and metabolism. Research has also explored the use of biomarkers, such as elevated inflammatory cytokines and decreased levels of brain-derived neurotrophic factor, as diagnostic tools, although clinical validation is still in progress. Clinically, CRCI can vary greatly in terms of both severity and duration, with some individuals experiencing transient symptoms and others suffering from chronic and progressive cognitive decline. Many of these symptoms overlap with those of depression and anxiety, complicating differential diagnosis and treatment.[4] Treatment strategies for CRCI are primarily symptomatic and multidisciplinary, focusing on cognitive rehabilitation programs, pharmacological agents such as methylphenidate, modafinil, and donepezil, and lifestyle interventions, including physical exercise and mindfulness-based stress reduction techniques. Additionally, the Food and Drug Administration has approved memantine, a drug primarily used for Alzheimer's disease, for managing cognitive symptoms in some cancer patients. A phase II single-arm trial also evaluated memantine for preventing cognitive decline due to chemotherapy for early-stage breast cancer.[5] Recent advances in neuroprotective strategies, such as the use of anti-inflammatory drugs and antioxidant supplementation, show promise in mitigating CRCI. However, further research and clinical trials are necessary to fully validate these treatments. Despite progress in understanding and managing CRCI, significant challenges remain, such as the lack of standardized diagnostic criteria and the heterogeneous nature of the disorder, which complicates both research and clinical management.[6]

## CASE STUDIES

Several human case studies and trials should be conducted. Longitudinal studies utilizing advanced neuroimaging, cognitive tests, and biomarker analyses to map changes in memory, attention, and executive functions over time could investigate the progression of neurocognitive impairments in patients undergoing chemotherapy. Comparative case-control studies can explore cognitive differences between chemotherapy-treated patients, non-treated patients, and healthy controls, identifying potential genetic or metabolic risk factors. One case study highlights significant cognitive impairments experienced by a breast cancer patient following adjuvant chemotherapy, including declines in processing speed, memory, and executive function. Notably, cognitive improvements were observed over time, with some domains approaching or reaching baseline levels after 12 years. This underscores the importance of acknowledging patients' subjective reports of cognitive changes and recognizing the potential for recovery with time and appropriate interventions. The findings emphasize the need for baseline cognitive assessments to accurately evaluate post-treatment changes, enabling the development of personalized support strategies for cancer survivors. The case also underscores the variability in individual experiences of cognitive impairments, such as memory and processing speed declines, in breast cancer patients undergoing adjuvant chemotherapy. It highlights the importance of addressing patients' subjective complaints and advocates for tailored interventions and support to foster long-term cognitive recovery.[7]

Additionally, a descriptive phenomenological study exploring the lived experiences of chemotherapy patients emphasizes that the "chemo brain" significantly affects concentration and memory. However, this issue often goes unrecognized by healthcare professionals. The study calls for improved communication, education, and acknowledgment of these impairments to empower patients. It also advocates for the development of coping strategies and the integration of supportive interventions, such as cognitive-behavioral therapies, to enhance the QoL for those affected.[8]

Another case studied a 66-year-old female breast cancer survivor with focus and memory impairments, or "chemo brain," following chemotherapy that ended 11 months prior. She also experienced lower extremity neuropathy, joint pain, and mild depression (Beck score of 17). Although her MoCA score of 27 was in the lower-normal range, she struggled with cognitive issues. Living with her husband, who provided feedback on BrightGo use, she showed improvements in all cognitive measures except NAB Word Generation, where performance remained normal. Both the participant and caregiver reported improved psychological well-being, sustained at follow-up. Although depression worsened initially, it decreased by 35% at follow-up, surpassing the Minimal Clinically Important Difference. She progressed from an average game difficulty of 3.3/16 to 12.5/16 by the last session.[9]

Interventional studies should test cognitive therapies, including computerized brain training, cognitive-behavioral therapy, and mindfulness practices. Lifestyle modification trials focusing on exercise, diet, and sleep optimization could assess their role in mitigating symptoms. The neuroprotective benefits of complementary therapies, such as acupuncture and yoga, should be explored in randomized trials. Chinese electroacupuncture can prevent "chemo brain", mitigate associated symptoms, and enhance the QoL in older cancer patients undergoing or about to begin

chemotherapy. Additionally, the safety of this intervention for these patients will be assessed. The findings from this study will help advocate for the use of electroacupuncture in chemotherapy patients and guide the development of future real-world research. Pharmacological trials using drugs like N-acetylcysteine, methylphenidate, donepezil, and omega-3 fatty acids could provide critical data on their effectiveness in treating chemo brain. Further studies involving pediatric, elderly, and comorbid populations could uncover tailored strategies for vulnerable groups. Real-world research is necessary to evaluate the practical implementation of findings, ensuring comprehensive care for cognitive health in cancer survivors. These studies would offer valuable insights into the pathophysiology, management, and therapeutic innovations for chemo brain.[10]

## DISCUSSION

The pathophysiology of CRCI is complex and multifactorial, involving neuroinflammation and mitochondrial dysfunction. Current diagnostic methods rely on subjective self-reports and neuroimaging, but there is a need for more reliable biomarkers. Treatment strategies remain largely symptomatic, and multidisciplinary approaches incorporating pharmacological and cognitive interventions are being explored. New therapeutic approaches, including anti-inflammatory drugs and antioxidants, hold potential, but require further validation through clinical trials. Case studies illustrate the significant variability in CRCI experiences among cancer survivors and emphasize the importance of personalized care and baseline cognitive assessments. The integration of coping strategies, such as cognitive-behavioral therapy and mindfulness, can significantly improve the QoL of affected individuals.

## CONCLUSION

CRCI remains a significant challenge for cancer survivors, affecting their cognitive function and QoL. While there is progress in understanding its pathophysiology and management, substantial gaps remain in diagnosis and treatment. Future research should focus on refining diagnostic tools, testing new pharmacological and non-pharmacological interventions, and developing personalized treatment strategies for CRCI to improve the long-term well-being of cancer survivors.

**Authors' contributions:** ST: Wrote the manuscript and referenced; KS: Critically revised the manuscript.

**Ethical approval:** Institutional Review Board approval is not required.
**Declaration of patient consent:** Patient's consent not required as there are no patients in this study.
**Financial support and sponsorship:** Nil.
**Conflicts of interest:** There are no conflicts of interest.

**Use of artificial intelligence (AI)-assisted technology for manuscript preparation:** The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

## REFERENCES

1. You W, Henneberg M. Cancer Incidence Increasing Globally: The Role of Relaxed Natural Selection. Evol Appl 2017;11:140-52.
2. Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan K, Santhappan S, *et al*. Cancer Statistics, 2020: Report from National Cancer Registry Programme, India. JCO Glob Oncol 2020;6:1063-75.
3. Ren X, Boriero D, Chaiswing L, Bondada S, St. Clair DK, Butterfield DA. Plausible Biochemical Mechanisms of Chemotherapy-induced Cognitive Impairment ('Chemobrain'), a Condition that Significantly Impairs the Quality of Life of Many Cancer Survivors. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:1088-97.
4. Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical Characteristics, Pathophysiology, and Management of Noncentral Nervous System Cancer-related Cognitive Impairment in Adults. CA A Cancer J Clinicians 2015;65:123-38.
5. Nakamura ZM, Deal AM, Park EM, Stanton KE, Lopez YE, Quillen LJ, *et al*. A Phase II Single-arm Trial of Memantine for Prevention of Cognitive Decline During Chemotherapy in Patients with Early Breast Cancer: Feasibility, Tolerability, Acceptability, and Preliminary Effects. Cancer Medicine 2023;12:8172-83.
6. Kohli S, Fisher S, Tra Y, Adams M, Mapstone M, Wesnes K, *et al*. The Effect of Modafinil on Cognitive Function in Breast Cancer Survivors. Cancer 2009;115:2605-16.
7. Fischer B. Breast Cancer Plus Adjuvant Chemotherapy-related Cognitive Impairment: A Case Study. Neurocase 2019;25:138-44.
8. Mitchell T, Turton P. 'Chemobrain': Concentration and Memory Effects in People Receiving Chemotherapy–a Descriptive Phenomenological Study. Eur J Cancer Care 2011;20:539-48.
9. Burdea G, Polistico K, Berde E. Home Virtual Rehabilitation for Early Alzheimer's or Chemobrain: Two Case Studies. Montreal, Canada: World Congress of the International Society on Virtual Rehabilitation.https://www.researchgate.net/profile/Grigore-Burdea/publication/379689334_Home_Virtual_Rehabilitation_for_Early_Alzheimer's_or_Chemobrain_Two_Case_Studies/links/66154de043f8df018dead48f/Home-Virtual-Rehabilitation-for-Early-Alzheimers-or-Chemobrain-Two-Case-Studies.pdf [Last accessed 2024 December 27].
10. Zhao S, Zhang J, Wan H, Tao C, Hu M, Liang W, *et al*. Role of Chinese Acupuncture in the Treatment for Chemotherapy-Induced Cognitive Impairment in Older Patients with Cancer: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2024;13:e53853.

**How to cite this article:** Sahu K, Tiwari S. The Impact of Chemotherapy on Cognitive Function: A Comprehensive Review of Cancer-related Cognitive Impairment and Treatment Options. Acad Bull Ment Health. 2025;3:4-6. doi: 10.25259/ABMH_1_2025